title: Relationship between ADH2 Arg47His variation and hepatocellular carcinoma susceptibility: a meta analysis.
abstract: BACKGROUND
  To further investigate the relationship between ADH2 Arg47His variation and hepatocellular carcinoma (HCC) susceptibility through a meta-analysis.
  
  
  METHODS
  The related articles were searched in PubMed, Embase and CNKI databases. And finally 518 cases and 607 controls were included in our meta-analysis Odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to assess the relationship between ADH2 Arg47His variation and HCC risk. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity.
  
  
  RESULTS
  Quantitative synthesis demonstrated that no significant association was found between ADH2 Arg47His variation and HCC susceptibility (His/His vs. Arg/Arg: OR=0.99, 95% CI=0.79-1.25; His/His + Arg/His vs. Arg/Arg: OR=1.01, 95% CI=0.86-1.20; His/His vs. Arg/Arg + Arg/His: OR=0.90, 95% CI=0.74-1.11; His vs. Arg: OR=0.98, 95% CI=0.86-1.11; Arg/His vs. Arg/Arg: OR=1.05, 95% CI=0.82-1.34).
  
  
  CONCLUSIONS
  Our analysis showed that ADH2 Arg47His vvariation may not be associated with HCC susceptibility.
authors: Clinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
authors: Shuzhen
authors: S
authors: Liu
authors: Department of Drug Clinical Trial Institution of Shandong Cancer Hospital & Institute Jinan, Shandong, China.
authors: Yongchun
authors: Y
authors: Cui
authors: Clinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
authors: Baohong
authors: B
authors: Yang
authors: Clinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
authors: Ping
authors: P
authors: Chai
authors: Clinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
authors: Zheng
authors: Z
authors: Su
authors: Clinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
authors: Qianqian
authors: Q
authors: Zhang
authors: Clinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
authors: Dejie
authors: D
authors: Zheng
authors: Clinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
authors: Rui
authors: R
authors: Li
authors: Clinical Oncology Department, Weifang People's Hospital Kuiwen District, Weifang, Shandong, China.
authors: Guohua
authors: G
authors: Yu
keywords: ADH2; hepatocellular carcinoma; variation